Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 50090-6889

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine Hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules. The structure includes aromatic and heterocyclic rings along with functional groups characteristic of duloxetine.*

FDA Label Image

Figure 1 (Duloxetine 02)

This is a line graph comparing the proportion of patients with relapse over time (up to 250 units, presumably days) between placebo and duloxetine delayed-release capsules. The graph shows two treatments: placebo with a dashed line and duloxetine delayed-release capsules with a solid line, indicating differences in relapse proportions over the study period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph showing the proportion of patients with relapse over time (days) from randomization. It compares two treatments: placebo (dashed line) and duloxetine delayed-release capsules (solid line), indicating a higher relapse proportion with placebo over a period up to 300 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Delayed-Release capsules at 20 mg once daily and 60 mg once and twice daily doses compared to placebo. The graph depicts patient improvement trends over increasing pain improvement thresholds.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60mg twice daily (BID), Duloxetine 60mg once daily (QD), and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows varying levels of pain improvement percentages from greater than 0 to 100%.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, with data points illustrating patient improvement rates across various pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved (y-axis) versus percent improvement in pain from baseline (x-axis) for different doses of duloxetine (20 mg, 60 mg, 120 mg once daily) compared to placebo. The graph displays trends for pain improvement across these treatment groups.*

FDA Label Image

Figure 7 (Duloxetine 08)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Two groups are compared: one treated with Duloxetine 60 mg once daily and another with placebo. The graph illustrates a higher percentage of improvement in pain for the Duloxetine group across different improvement thresholds.*

FDA Label Image

Figure 8 (Duloxetine 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, plotting data for a placebo group and a group taking DUL 60/120 mg once daily. The graph shows that higher percentages of patients improved with DUL treatment across increasing percent improvements in pain.*

FDA Label Image

Figure 9 (Duloxetine 10)

A line graph comparing the percentage of patients improved with DUL 60 mg once daily versus placebo across varying percentages of pain improvement from baseline (BOCF). The graph shows two lines depicting patient improvement trends for placebo and DUL 60 mg over a range of pain improvement percentages from greater than 0 to 100.*

FDA Label Image

Figure 10 (Duloxetine 11)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF). Two lines represent placebo and Duloxetine at 60/120 mg once daily, showing patient improvement percentages decreasing as pain improvement percentage increases.*

FDA Label Image

Label Image (Lbl500906889)

Label for Duloxetine Delayed-Release capsules containing 20 mg of duloxetine hydrochloride per capsule. The label indicates storage instructions to keep at 77 degrees and a package count of 90 capsules. It is produced by A-S Medication Solutions in Libertyville, Illinois, and includes NDC 50090-6889-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.